ABCC7 p.Gly723*
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 10933805
[PubMed]
King SA et al: "R-domain interactions with distal regions of CFTR lead to phosphorylation and activation."
No.
Sentence
Comment
27
1 Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ABC, ATP binding cassette; NBD, nucleotide binding domain; TMD, transmembrane domain; R-domain, regulatory domain; PKA, cyclic AMP-dependent protein kinase A; His P, NBD of histidine permease; His Q and His M, TMDs of histidine permease; Mal K, NBD region of the maltose transport system; Mal F, integral membrane protein of the maltose transport system; AMP, adenosine monophosphate; ∆R-CFTR, CFTR lacking amino acids 708-835; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; DMEM, Dulbecco`s Modified Eagle`s Medium; FBS, fetal bovine serum; vTF7.3, vaccina virus encoding the T7 polymerase; MOI, multiplicity of infection; DOC, deoxycholic acid; PVDF, poly- (vinylidene difluoride); NBT, 4-nitroblue tetrazolium chloride; SPQ, 6-methoxy-N-(3-sulfopropyl)quinolonium; BCIP, 5-bromo-4-chloro-3-indolyl phosphate; -gal, -galactosidase; ∆1-836, carboxy hemi-CFTR beginning immediately after the R-domain; M837X, CFTR truncation that ends at CFTR position 836, after the R-domain; G723X, CFTR truncation ending at residue 722 within the R-domain; K593X, CFTR truncation ending immediately before the R-domain at position 592.
X
ABCC7 p.Gly723* 10933805:27:1110
status: NEW53 The resulting product was inserted between the SphI and StuI sites of pTM-CFTR, to place a premature stop codon in place of CFTR amino acid 837. pTM-G723X was constructed using a similar strategy but with a stop codon in place of the glycine at residue 723.
X
ABCC7 p.Gly723* 10933805:53:149
status: NEW173 G723X (missing the 114 C-terminal amino acids of the R-domain, Table 1) was tested for the phosphorylation-dependent mobility shift following coexpression with ∆1-836.
X
ABCC7 p.Gly723* 10933805:173:0
status: NEW174 While G723X co-immunoprecipitated with ∆1-836 in a manner similar to that of M837X, this interaction did not result in a mobility shift of the G723X protein (Figure 7A, compare lanes 3 and 4).
X
ABCC7 p.Gly723* 10933805:174:6
status: NEWX
ABCC7 p.Gly723* 10933805:174:150
status: NEW175 Furthermore, no molecular weight shift of G723X could be detected when cells were treated with forskolin prior to lysis (Figure 7B, lane 4).
X
ABCC7 p.Gly723* 10933805:175:42
status: NEW176 G723X and ∆1-836 expressed together produced constitutive (unregulated) activity (Figure 8A).
X
ABCC7 p.Gly723* 10933805:176:0
status: NEW179 K593X (CFTR truncated immediately before the R-domain, Table 1) co-immunoprecipitated with ∆1-836 in a manner similar to that of M837X or G723X (data not shown), but coexpression of K593X with ∆1-836 failed to produce enhanced halide efflux (Figure 8A).
X
ABCC7 p.Gly723* 10933805:179:145
status: NEW188 A shorter amino truncation (G723X) also tightly bound to ∆1-836.
X
ABCC7 p.Gly723* 10933805:188:28
status: NEW189 In contrast to M837X, G723X failed to exhibit a reduced mobility on SDS-PAGE after either coexpression with ∆1FIGURE 6: Halide permeability produced by M837X and ∆1-836 is PKA-dependent.
X
ABCC7 p.Gly723* 10933805:189:22
status: NEW197 FIGURE 7: G723X binds ∆1-836, but this interaction does not elicit a mobility shift of G723X.
X
ABCC7 p.Gly723* 10933805:197:10
status: NEWX
ABCC7 p.Gly723* 10933805:197:94
status: NEW199 While both G723X and M837X bind ∆1-836 (lanes 3 and 4), only the interaction of M837X with ∆1-836 produced a higher-molecular weight phosphorylated protein (*, lane 3).
X
ABCC7 p.Gly723* 10933805:199:11
status: NEW200 (B) Cells expressing M837X or G723X were treated with forskolin prior to lysis (as described in the legend of Figure 4).
X
ABCC7 p.Gly723* 10933805:200:30
status: NEW202 However, forskolin treament of cells expressing G723X did not result in a higher-molecular weight protein (lane 4).
X
ABCC7 p.Gly723* 10933805:202:48
status: NEW211 G723X also produced high basal halide efflux when it was coexpressed with ∆1-836 (Figure 8A).
X
ABCC7 p.Gly723* 10933805:211:0
status: NEW228 FIGURE 8: G723X coexpression with ∆1-836 produces enhanced halide efflux, while K593X does not.
X
ABCC7 p.Gly723* 10933805:228:10
status: NEW229 (A) G723X and ∆1-836 (9) or K593X and ∆1-836 (b) were expressed in COS7 cells, and halide efflux was assayed as described in the legend of Figure 5.
X
ABCC7 p.Gly723* 10933805:229:4
status: NEW230 G723X produced high basal halide permeability when coexpressed with ∆1-836 (p < 0.01) similar to that of M837X with ∆1-836 (Figure 5).
X
ABCC7 p.Gly723* 10933805:230:0
status: NEW234 (B) M837X and ∆1-836 (0) or G723X and ∆1-836 (O) were expressed in COS7 cells and assayed for halide movement as described in the legend of Figure 6.
X
ABCC7 p.Gly723* 10933805:234:35
status: NEW235 Rp-8-CPT- cAMPS inhibited the enhanced halide permeability of M837X and ∆1-836 (9, p < 0.05), but not that of G723X and ∆1-836 (b).
X
ABCC7 p.Gly723* 10933805:235:117
status: NEW